Pharmacogenetic evaluation of oxicodone in patients. - ND

AZIENDA OSPEDALIERA PISANA0 个研究点开始时间: 2008年4月10日最近更新: 2012年3月19日

试验速览

暂无简介。

•a. Patients of either sex aged 18-80 years; b. Chronic pain; c. Patients scheduled to receive oxycodon; d. Informed consent signed by the patient, relatives or legal representative.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•a. Contraindications to oxycodone treatment; b. Previous/concomitant treatment with systemic drugs known to affect oxycodone absorption/distribution/excretion or to interact with oxycodone; c. Renal functional impairment (creatinine clearance < 50 ml/min); d. Serious concomitant disease, including but not restricted to renal insufficiency, major cardiac disease (arrhythmias), edema, diastolic blood pressure > 100 mmHg, hypertension, significant cardiovascular or pulmonary dysfunction in the previous 6 months, immunodeficiency syndromes (e.g. HIV, disease requiring immunosuppressive therapy); e. For sexually active female patients: absence of adequate contraceptive measures, pregnancy, breast feeding; f. Alcohol abuse (ethanol intake > 210 g for week within the previous 1 year, i.e. > 2 bottles of beer or > 3 glasses of wine per day).

发起方

AZIENDA OSPEDALIERA PISANA